Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Des pas en alimentation durable mais trop petits pour bien nourrir tout le Qubec
Dévoilement de la politique bioalimentaire 2025-2035 August 22, 2025 12:52 ET |…
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show…
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
